Shots:

• The approval is based on P-III studies KX01-AK-003 and KX01-AK-004 that evaluated the efficacy and safety of Klisyri (tirbanibulin- ointment 1%- 10 mg/g) vs vehicle in 702 adult patients in the ratio of (1:1) with actinic keratosis of the face or scalp
• Both the studies achieved their 1EPs defined as 100% clearance of the AK lesions @57 days within the treatment areas- complete clearance (44% vs 5% and 54% vs 13%) respectively
• Klisyri is the first FDA approved product for Athenex and will be launched in partnership with Almirall in the US during Q1’21

 ­ Ref: GlobeNewswire | Image: Athenex